The DOI matches its Crossref record; 91 of the 93 references it cites were found in a registry or an index.
The Epithelial-to-Mesenchymal Transition (EMT) in the Development and Metastasis of Malignant Pleural Mesothelioma
Open accessAbstract
Malignant pleural mesothelioma (MPM) is an aggressive tumor mainly associated with asbestos exposure and is characterized by a very difficult pharmacological approach. One of the molecular mechanisms associated with cancer onset and invasiveness is the epithelial-to-mesenchymal transition (EMT), an event induced by different types of inducers, such as transforming growth factor β (TGFβ), the main inducer of EMT, and oxidative stress. MPM development and metastasis have been correlated to EMT; On one hand, EMT mediates the effects exerted by asbestos fibers in the mesothelium, particularly via increased oxidative stress and TGFβ levels evoked by asbestos exposure, thus promoting a malignant phenotype, and on the other hand, MPM acquires invasiveness via the EMT event, as shown by an upregulation of mesenchymal markers or, although indirectly, some miRNAs or non-coding RNAs, all demonstrated to be involved in cancer onset and metastasis. This review aims to better describe how EMT is involved in driving the development and invasiveness of MPM, in an attempt to open new scenarios that are useful in the identification of predictive markers and to improve the pharmacological approach against this aggressive cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ROS can sustain EMT via TGF-β1 [89].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [89]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Adhikary, G., Grun, D., Alexander, H. R., Friedberg, J. S., Xu, W., Keillor, J. W., Kandasamy, S., & Eckert, R. L. (2018) · Oncotarget · doi:10.18632/oncotarget.26130 · Cited by 40
RetractedNew insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
Dongre, A., & Weinberg, R. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0080-4 · Cited by 3,876
Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121
TGF-β-induced epithelial to mesenchymal transition
Xu, J., Lamouille, S., & Derynck, R. (2009) · Cell Research · doi:10.1038/cr.2009.5 · Cited by 2,804 · cited 1×
“In a non-SMAD-dependent way, TGFβ-induced EMT involves some signaling pathways, such as mitogen-activated protein kinase (MAPK), PI3K, NF-κB and small GTPases of the Rho family [4,48,49]; among these non-SMAD signaling pathways, PI3K actives Akt, which inhibits GSK-3β in turn, a regulator of SNAI1, SNAI2, Twist and ZE…”
BackgroundGuidelines and definitions for research on epithelial-mesenchymal transition
Yang, J., Antin, P., Berx, G., Blanpain, C., Brabletz, T., Bronner, M., Campbell, K., Cano, A., Casanova, J., Christofori, G., et al. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0237-9 · Cited by 2,226
Burk, U., Schubert, J., Wellner, U., Schmalhofer, O., Vincan, E., Spaderna, S., & Brabletz, T. (2008) · EMBO reports · doi:10.1038/embor.2008.74 · Cited by 1,722
Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32714-8 · Cited by 1,215 · cited 2×
“Currently, a combination of immune checkpoint inhibitors (ICIs), monoclonal antibodies (mAbs), anti-programmed cell death 1 (PD-1), nivolumab and anti-CTL antigen 4 (CTLA-4) ipilimumab [10] was approved by the Food and Drug Administration (FDA) for first-line treatment of unresectable MPM based on CheckMate 743, which…”
BackgroundMethodTGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis
Hao, Y., Baker, D., & ten Dijke, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112767 · Cited by 1,142
Woo, E. Y., Chu, C., Goletz, T. J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S. C., Kaiser, L. R., & June, C. H. (2001) · PubMed · Cited by 1,108
Malignant cells facilitate lung metastasis by bringing their own soil
Duda, D. G., Duyverman, A. M. M. J., Kohno, M., Snuderl, M., Steller, E. J. A., Fukumura, D., & Jain, R. K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016234107 · Cited by 594
A Switch in the Expression of Embryonic EMT-Inducers Drives the Development of Malignant Melanoma
Caramel, J., Papadogeorgakis, E., Hill, L., Browne, G. J., Richard, G., Wierinckx, A., Saldanha, G., Osborne, J., Hutchinson, P., Tse, G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.018 · Cited by 517
Tumor Immune Microenvironment during Epithelial–Mesenchymal Transition
Taki, M., Abiko, K., Ukita, M., Murakami, R., Yamanoi, K., Yamaguchi, K., Hamanishi, J., Baba, T., Matsumura, N., & Mandai, M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4459 · Cited by 351
Diseases caused by silica: mechanisms of injury and disease development
Ding, M., Chen, F., Shi, X., Yucesoy, B., Mossman, B., & Vallyathan, V. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(01)00170-9 · Cited by 350
MIYAZONO, K. (2009) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.85.314 · Cited by 337
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
Bibby, A. C., Tsim, S., Kanellakis, N., Ball, H., Talbot, D. C., Blyth, K. G., Maskell, N. A., & Psallidas, I. (2016) · European Respiratory Review · doi:10.1183/16000617.0063-2016 · Cited by 316
HSP70 Multi-Functionality in Cancer
Albakova, Z., Armeev, G. A., Kanevskiy, L. M., Kovalenko, E. I., & Sapozhnikov, A. M. (2020) · Cells · doi:10.3390/cells9030587 · Cited by 265
Asbestos-induced lung diseases: an update
Kamp, D. W. (2009) · Translational Research · doi:10.1016/j.trsl.2009.01.004 · Cited by 251
Targeting EMT in Cancer with Repurposed Metabolic Inhibitors
Ramesh, V., Brabletz, T., & Ceppi, P. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.06.005 · Cited by 243
Cannito, S., Novo, E., di Bonzo, L. V., Busletta, C., Colombatto, S., & Parola, M. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2737 · Cited by 239 · cited 15×
“Several studies have shown that asbestos can induce EMT; human mesothelial cells exposed to asbestos fibers promote the release of HMGB1 and TNF-α, which in turn mediate EMT, thus ensuring cell survival and protecting cells from asbestos cytotoxicity [8].”
BackgroundInfluentialEMT and Oxidative Stress: A Bidirectional Interplay Affecting Tumor Malignancy
Giannoni, E., Parri, M., & Chiarugi, P. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4280 · Cited by 231
Diseases caused by asbestos: mechanisms of injury and disease development
Manning, C. B., Vallyathan, V., & Mossman, B. T. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(01)00172-2 · Cited by 228
Krstić, J., Trivanović, D., Mojsilović, S., & Santibanez, J. F. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/654594 · Cited by 225
TGF-β Synergizes with Defects in the Hippo Pathway to Stimulate Human Malignant Mesothelioma Growth
Fujii, M., Toyoda, T., Nakanishi, H., Yatabe, Y., Sato, A., Matsudaira, Y., Ito, H., Murakami, H., Kondo, Y., Kondo, E., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111653 · Cited by 224
Malignant Mesothelioma and Its Non-Asbestos Causes
Attanoos, R. L., Churg, A., Galateau-Salle, F., Gibbs, A. R., & Roggli, V. L. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0365-ra · Cited by 223
Ramachandran, A., Vizán, P., Das, D., Chakravarty, P., Vogt, J., Rogers, K. W., Müller, P., Hinck, A. P., Sapkota, G. P., & Hill, C. S. (2018) · eLife · doi:10.7554/elife.31756 · Cited by 204
Epithelial plasticity, epithelial-mesenchymal transition, and the TGF-β family
Katsuno, Y., & Derynck, R. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.02.028 · Cited by 187
Therapeutic implications of cancer epithelial-mesenchymal transition (EMT)
Cho, E. S., Kang, H. E., Kim, N. H., & Yook, J. I. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-018-01108-7 · Cited by 180
(1987) · PubMed · Cited by 176
Tobar, N., Villar, V., & Santibanez, J. F. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0418-5 · Cited by 168
Epithelial-Mesenchymal Transition and Metastasis under the Control of Transforming Growth Factor β
Tsubakihara, Y., & Moustakas, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113672 · Cited by 160
Arsalane, K., Dubois, C. M., Muanza, T., Bégin, R., Boudreau, F., Asselin, C., & Cantin, A. M. (1997) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.17.5.2833 · Cited by 159
Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy
Raskov, H., Orhan, A., Gaggar, S., & Gögenur, I. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668731 · Cited by 150
Asbestos-Derived Reactive Oxygen Species Activate TGF-Β1
Pociask, D. A., Sime, P. J., & Brody, A. R. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700109 · Cited by 149 · cited 4×
“Among these inducers of EMT, which can be also released by the tumor cell, there are growth factors such as the transforming growth factor β (TGFβ) and the hepatocyte growth factor (HGF), as well as cytokines, which include the tumor necrosis factor α (TNFα) [3,40].”
BackgroundInfluentialMicroRNA Control of TGF-β Signaling
Suzuki, H. I. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071901 · Cited by 148
He, X., Wang, L., Riedel, H., Wang, K., Yang, Y. S., Dinu, C. Z., & Rojanasakul, Y. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0633-8 · Cited by 145
Sarcomatoid mesothelioma: a clinical–pathologic correlation of 326 cases
Klebe, S., Brownlee, N. A., Mahar, A. M., Burchette, J. L., Sporn, T. A., Vollmer, R. T., & Roggli, V. L. (2010) · Modern Pathology · doi:10.1038/modpathol.2009.180 · Cited by 143
Qi, F., Okimoto, G., Jube, S., Napolitano, A., Pass, H. I., Laczkó, R., DeMay, R. M., Khan, G., Tiirikainen, M., Rinaudo, C., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.07.029 · Cited by 125
Quetel, L., Meiller, C., Assié, J., Blum, Y., Imbeaud, S., Montagne, F., Tranchant, R., Wolf, J. D., Caruso, S., Copin, M., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12651 · Cited by 123
The relationship between vasculogenic mimicry and epithelial‐mesenchymal transitions
Liu, Q., Qiao, L., Liang, N., Xie, J., Zhang, J., Deng, G., Luo, H., & Zhang, J. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12851 · Cited by 122
İmani, S., Hosseinifard, H., Cheng, J., Wei, C., & Fu, J. (2016) · Scientific Reports · doi:10.1038/srep28587 · Cited by 122
DeLong, P. A., Carroll, R. G., Henry, A. C., Tanaka, T. N., Ahmad, S., Leibowitz, M. S., Sterman, D. H., June, C. H., Albelda, S. Μ., & Vonderheide, R. H. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.3.1644 · Cited by 120
Song, W., Mazzieri, R., Yang, T., & Gobe, G. C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01106 · Cited by 112
How Asbestos and Other Fibers Cause Mesothelioma
Gaudino, G., Xue, J., & Yang, H. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.02.01 · Cited by 102
The multiverse nature of epithelial to mesenchymal transition
Simeone, P., Trerotola, M., Franck, J., Cardon, T., Marchisio, M., Fournier, I., Salzet, M., Maffia, M., & Vergara, D. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.11.004 · Cited by 98
Kong, F., Qu, Z., YUAN, H.-H., Wang, J., Zhao, M., Guo, Y., SHI, J., Gong, X., Zhu, Y., Liu, F., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3129 · Cited by 95
Prognostic significance of epithelial–mesenchymal transition in malignant pleural mesothelioma☆☆☆
Schramm, A., Opitz, I., Thies, S., Seifert, B., Moch, H., Weder, W., & Soltermann, A. (2009) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2009.08.027 · Cited by 89
Pleural mesothelioma classification update
Beasley, M. B., Galateau-Sallé, F., & Đačić, S. (2021) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-021-03031-7 · Cited by 88
Asbestos fiber length and its relation to disease risk
Barlow, C. A., Grespin, M., & Best, E. A. (2017) · Inhalation Toxicology · doi:10.1080/08958378.2018.1435756 · Cited by 83
Fitzpatrick, D. R., Peroni, D. J., & Bielefeldt‐Ohmann, H. (1995) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.12.5.7742009 · Cited by 81
Farrell, J., Kelly, C., Rauch, J., Kida, K., García-Muñoz, A., Monsefi, N., Turriziani, B., Doherty, C., Mehta, J. P., Matallanas, D., et al. (2014) · Journal of Proteome Research · doi:10.1021/pr5000285 · Cited by 77
Non-Neoplastic and Neoplastic Pleural Endpoints Following Fiber Exposure
Broaddus, V. C., Everitt, J. I., Black, B., & Kane, A. B. (2011) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/10937404.2011.556049 · Cited by 74
Kim, M., Cui, F., & Kim, Y. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.6.3625 · Cited by 74
Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma
Hiltbrunner, S., Mannarino, L., Kirschner, M. B., Opitz, I., Rigutto, A., Laure, A., Lia, M., Nozza, P., Maconi, A., Marchini, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.660039 · Cited by 62
Shah, P. P., Dupre, T. V., Siskind, L. J., & Beverly, L. J. (2017) · Oncotarget · doi:10.18632/oncotarget.15150 · Cited by 59
Schelch, K., Wagner, C., Hager, S., Pirker, C., Siess, K. M., Lang, E., Lin, R. C. Y., Kirschner, M. B., Mohr, T. T., Brčić, L., et al. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy018 · Cited by 51
Intracellular protein binding to asbestos induces aneuploidy in human lung fibroblasts
MacCorkle, R. A., Slattery, S. D., Nash, D. R., & Brinkley, B. R. (2006) · Cell Motility and the Cytoskeleton · doi:10.1002/cm.20151 · Cited by 49
Hypoxia Promotes Acquisition of Aggressive Phenotypes in Human Malignant Mesothelioma
Kim, M.-C., Hwang, S.-H., Kim, N.-Y., Lee, H.-S., Ji, S., Yang, Y., & Kim, Y. (2018) · BMC Cancer · doi:10.1186/s12885-018-4720-z · Cited by 49
Li, C., Rezov, V., Joensuu, E. I., Vartiainen, V. A., Rönty, M. J., Yin, M., Myllärniemi, M., & Koli, K. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-28297-x · Cited by 48
MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets.
Reid, G. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2015.04.56 · Cited by 47
Trempolec, N., Degavre, C., Doix, B., Brusa, D., Corbet, C., & Féron, O. (2020) · Cancers · doi:10.3390/cancers12051284 · Cited by 47
Antiangiogeneic Strategies in Mesothelioma
Nowak, A. K., Brosseau, S., Cook, A., & Zalcman, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00126 · Cited by 45
Turini, S., Bergandi, L., Gazzano, E., Prato, M., & Aldieri, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010150 · Cited by 44 · cited 2×
“Finally, it has been demo strated that asbestos fi rs exposur induces EMT in human mesothelial cells through a mechanism mediated by TGF-β, which in turn, via he SMAD pathway, leads to Twist, ZEB and Snail overexpression [63].”
BackgroundSelf-citationManipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future
Reid, G., Johnson, T. G., & van Zandwijk, N. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00105 · Cited by 42
Tamminen, J. A., Yin, M., Rönty, M. J., Sutinen, E., Pasternack, A. H., Ritvos, O., Myllärniemi, M., & Koli, K. M. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.12.010 · Cited by 39
Matsumoto, S., Nabeshima, K., Hamasaki, M., Shibuta, T., & Umemura, T. (2014) · Medical Oncology · doi:10.1007/s12032-014-0303-2 · Cited by 37
Casarsa, C., Bassani, N., Ambrogi, F., Zabucchi, G., Boracchi, P., Biganzoli, E. M., & Coradini, D. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.01.009 · Cited by 36
Gremlin-1 Is a Key Regulator of the Invasive Cell Phenotype in Mesothelioma
Yin, M., Tissari, M., Tamminen, J., Ylivinkka, I., Rönty, M., von Nandelstadh, P., Lehti, K., Hyytiäinen, M., Myllärniemi, M., & Koli, K. (2017) · Oncotarget · doi:10.18632/oncotarget.21550 · Cited by 33
Sohn, E. J., Won, G., Lee, J., Yoon, S.-W., Lee, I., Kim, H. J., & Kim, S. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.13453 · Cited by 32
CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials
Chintala, N. K., Restle, D. J., Quach, H. T., Saini, J. K., Bellis, R. Y., Offin, M. D., Beattie, J., & Adusumilli, P. S. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.05.004 · Cited by 32
Wan, T., Zhang, T., Si, X., & Zhou, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.18352 · Cited by 30
The role of intracavitary therapies in the treatment of malignant pleural mesothelioma
Bertoglio, P., Aprile, V., Ambrogi, M. C., Mussi, A., & Lucchi, M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.10.165 · Cited by 30
Expression of snail, twist, and Zeb1 in malignant mesothelioma
Merikallio, H., Pääkkö, P., Salmenkivi, K., Kinnula, V., Harju, T., & Soini, Y. (2013) · Apmis · doi:10.1111/j.1600-0463.2012.02931.x · Cited by 29
Stathmin is overexpressed in malignant mesothelioma.
Kim, J. Y., Harvard, C., You, L., Xu, Z., Kuchenbecker, K. M., Baehner, F. L., & Jablons, D. M. (2007) · PubMed · Cited by 26
Stockhammer, P., Plönes, T., Theegarten, D., Schüler, M., Maier, S. M., Aigner, C., & Hegedűs, B. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.11.013 · Cited by 26
Asbestos Exposure Induces Alveolar Epithelial Cell Plasticity through MAPK/Erk Signaling
Tamminen, J. A., Myllärniemi, M., Hyytiäinen, M., Keski‐Oja, J., & Koli, K. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24094 · Cited by 25 · cited 1×
“A prognostic value has even been associated with EMT markers in malignant mesotheliomas [20] and in metastatic lung adenocarcinomas [36].”
BackgroundTargeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma
Birnie, K. A., Prêle, C. M., Thompson, P. J., Badrian, B., & Mutsaers, S. E. (2017) · Oncotarget · doi:10.18632/oncotarget.20409 · Cited by 23
Immunotherapy in malignant pleural mesothelioma: a review of literature data
Menis, J., Pasello, G., & Remón, J. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-673 · Cited by 23
Gulino, G. R., Polimeni, M., Prato, M., Gazzano, E., Kopecka, J., Colombatto, S., Ghigo, D., & Aldieri, E. (2016) · Environmental Health Perspectives · doi:10.1289/ehp.1409627 · Cited by 22
Self-citationIwanami, T., Uramoto, H., Nakagawa, M., Shimokawa, H., Yamada, S., Kohno, K., & Tanaka, F. (2014) · Oncology · doi:10.1159/000356874 · Cited by 21
Singh, A. N., Heery, R., & Gray, S. G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051297 · Cited by 21
Sakai, K., Inoue, M., Mikami, S., Nishimura, H., Kuwabara, Y., Kojima, A., Toda, M., Ogawa‐Kobayashi, Y., Kikuchi, S., Hirata, Y., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13784 · Cited by 21
Liu, J., Bao, J., HAO, J., Yan, P., & HONG, F. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2279 · Cited by 20
Vasculogenic mimicry in malignant mesothelioma: an experimental and immunohistochemical analysis
Pulford, E., Hocking, A. J., Griggs, K. M., McEvoy, J., Bonder, C. S., Henderson, D. W., & Klebe, S. (2016) · Pathology · doi:10.1016/j.pathol.2016.07.009 · Cited by 18
Nader, J. S., Guillon, J., Petit, C., Boissard, A., Franconi, F., Blandin, S., Lambot, S., Grégoire, M., Verrièle, V., Nawrocki‐Raby, B., et al. (2020) · Cancers · doi:10.3390/cancers12040939 · Cited by 18
Okazaki, Y., Chew, S. H., Nagai, H., Yamashita, Y., Ohara, H., Jiang, L., Akatsuka, S., Takahashi, T., & Toyokuni, S. (2020) · Cancer Science · doi:10.1111/cas.14405 · Cited by 15
Wirawan, A., Tajima, K., Takahashi, F., Mitsuishi, Y., Winardi, W., Hidayat, M., Hayakawa, D., Matsumoto, N., Izumi, K., Asao, T., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0230 · Cited by 15
Lee, Y.-J., Park, K.-S., Heo, S., Nam, H.-S., Cho, M. K., & Lee, S.-H. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01181-6 · Cited by 10
MicroRNAs diagnostic and prognostic value as predictive markers for malignant mesothelioma
Sturchio, E., Berardinelli, M. G., Boccia, P., Zanellato, M., & Gioiosa, S. (2020) · Archives of Environmental & Occupational Health · doi:10.1080/19338244.2020.1747966 · Cited by 9
Wirawan, A. (2020) · Institutional Repositories DataBase (IRDB) · Cited by 8
Urso, L., Silic‐Benussi, M., Boscolo, A., Lorenzi, M., Bonanno, L., Lunardi, F., Guarneri, V., Calabrese, F., Rea, F., Conte, P., et al. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155622 · Cited by 5
Pleural effusion TGF-beta is highly diagnostic and prognostic in malignant pleural mesothelioma
Stockhammer, P., Ploenes, T., Schüler, M., Langer, S. W., Aigner, C., & Hegedűs, B. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz266.008 · Cited by 1
Cited by
Fiorilla, I., Martinotti, S., Todesco, A. M., Bonsignore, G., Cavaletto, M., Patrone, M., Ranzato, E., & Audrito, V. (2023) · Cells · doi:10.3390/cells12162048 · Cited by 39
Fennell, D. A., Sekido, Y., Baas, P., Husain, A. N., Fontecedro, A. C., Lim, E. K. S., Opitz, I., Simone, C. B., Brims, F., & Wong, M. C. S. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00640-3 · Cited by 47
“The exact cause of EMT in mesothelioma remains unclear, but it likely involves the acquisition of genomic abnormalities, positive selection of tumour cells and the tumour microenvironment (TME), which includes stimulation by TGFβ 66 .”
InfluentialFakhri, S., Moradi, S. Z., Faraji, F., Kooshki, L., Webber, K. J., & Bishayee, A. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10136-9 · Cited by 34
TGF-β as Predictive Marker and Pharmacological Target in Lung Cancer Approach
Ramundo, V., Palazzo, M. L., & Aldieri, E. (2023) · Cancers · doi:10.3390/cancers15082295 · Cited by 35
“In particular, this cytokine is the major driver of the epithelial to mesenchymal transition (EMT), a reversible physiological process involved in tumor onset, progression, and metastasis [8].”
BackgroundSelf-citationAbd‐Elmawla, M. A., Mageed, S. S. A., AL‐Noshokaty, T. M., Elballal, M. S., Abulsoud, A. I., Elshaer, S. S., El-Husseiny, A. A., Fathi, D., Midan, H. M., Rizk, N. I., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154817 · Cited by 26
Metadata
- Authors
- Ramundo, V., Zanirato, G., & Aldieri, E.
- Affiliations
- University of Turin (IT)
- Corresponding author
- Aldieri, Elisabetta
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-11-11
- Volume
- 22
- Issue
- 22
- Pages
- 12216
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8621591
- OpenAlex
- W3214151214
- Cited by
- 46
- References
- 93
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 6 · 2023: 14 · 2022: 10
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- epithelial-mesenchymal transition, malignant pleural mesothelioma, asbestos exposure, TGF-beta, oxidative stress, tumor invasion, metastasis, mesenchymal markers, microRNA, non-coding RNA, predictive biomarkers, mesothelium
- MeSH terms
- Mesothelioma, Malignant, Humans, Neoplasm Metastasis, Neoplasm Proteins, Pleural Neoplasms, RNA, Neoplasm, Biomarkers, Tumor, Transforming Growth Factor beta, MicroRNAs, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.